论文部分内容阅读
目的探讨子宫内膜癌患者癌组织中ESM-1和β-arrestin-2蛋白阳性强度的表达及相关性。方法选取子宫内膜癌、子宫内膜不典型增生、正常子宫内膜标本各30例,采用免疫组织化学染色法检测各组ESM-1和β-arrestin-2蛋白阳性强度的表达及二者的相关性。结果与正常子宫内膜组比较,子宫内膜癌、子宫内膜不典型增生组ESM-1和β-arrestin-2蛋白阳性表达强度均明显升高,差异有统计学意义(P<0.01),且前者高于后者;ESM-1和β-arrestin-2在组织中蛋白阳性表达强度呈正相关性(r=0.624,P<0.05)。结论 ESM-1和β-arrestin-2蛋白参与子宫内膜癌的发生、发展过程,其作用机制有待于进一步研究。
Objective To investigate the expression and correlation of ESM-1 and β-arrestin-2 protein in cancer tissues of endometrial cancer patients. Methods Thirty cases of endometrial carcinoma, atypical endometrial hyperplasia and normal endometrium were selected. Immunohistochemical staining was used to detect the expression of ESM-1 and beta-arrestin-2 in each group, Correlation. Results Compared with normal endometrium group, the positive expression rates of ESM-1 and β-arrestin-2 protein in endometrial carcinoma and endometrial dysplasia group were significantly higher than those in normal endometrium group (P <0.01) And the former was higher than the latter. The positive expression of ESM-1 and β-arrestin-2 in the tissues was positively correlated (r = 0.624, P <0.05). Conclusion ESM-1 and β-arrestin-2 are involved in the pathogenesis and development of endometrial carcinoma. The mechanism of ESM-1 and β-arrestin-2 remains to be further studied.